Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Hoofdauteurs: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Formaat: | Journal article |
Gepubliceerd in: |
Lancet
2016
|
Gelijkaardige items
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
door: Glaire, MA, et al.
Gepubliceerd in: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
door: Van Gool, I, et al.
Gepubliceerd in: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
door: Klenerman, P, et al.
Gepubliceerd in: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
door: Van Gool, I, et al.
Gepubliceerd in: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
door: Rayner, E, et al.
Gepubliceerd in: (2016)